Skip to main content
SpringerLink
Log in

Stem Cell Sources

Peripheral Blood Stem Cells and Bone Marrow for Allogeneic Transplantation

  • Chapter
Stem Cell Transplantation for Hematologic Malignancies

Part of the book series: Contemporary Hematology ((CH))

Abstract

The discovery that human hematopoietic progenitors are found in the peripheral circulation and can be harvested for use in stem cell transplantation (SCT) has been both a scientifically enlightening and a clinically useful observation in SCT technology. Over the past decade, our understanding of peripheral blood stem cell (PB SC) properties has increased dramatically, and as a consequence, the use of PBSCs in autologous and allogeneic transplantation has increased exponentially. PBSCs have rapidly become the stem cell of choice for nearly all patients undergoing autologous transplantation because of their ease of collection and rapid engraftment. In the allogeneic setting, there have been dramatic increases in the use of PBSCs; however, many centers do not yet have adequate facilities to collect PBSCs from allogeneic donors and some centers have chosen not to adapt PBSCs as the main source for allogeneic stem cells for a variety of reasons. In the autologous setting, the broad adoption of peripheral blood stem cell transplantation (PBSCT) has been beneficial, with more rapid time to engraftment and less in-hospital morbidity noted after transplant. In the allogeneic setting, however, these data are less mature and there are observations that suggest that some of the putative advantages of PBSCT in the allogeneic setting may have substantial limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eapen M. IBMTR/ABMTR Newslett 2002;9(1).

    Google Scholar 

  2. Ringdén O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655–4664.

    Article  PubMed  Google Scholar 

  3. Abkowitz 7L. Can human hematopoietic stem cells become skin, gut, or liver cells? N Engl J Med 2002; 346 (10): 770–772.

    Article  Google Scholar 

  4. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81 (7): 1883–1889.

    PubMed  CAS  Google Scholar 

  5. McCullough J, Clay M, Herr G, et al. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999; 39 (10): 1136–1140.

    Article  PubMed  CAS  Google Scholar 

  6. Murata M, Harada M, Kato S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24 (10): 1065–1071.

    Article  PubMed  CAS  Google Scholar 

  7. Demirer T, Ayli M, Ozcan M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116 (2): 468–474.

    Article  PubMed  CAS  Google Scholar 

  8. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte—macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002; 9 (3): 190–198.

    Article  PubMed  Google Scholar 

  9. Kröger N, Renges H, Sonnenberg S, et al. Stem cell mobilisation with 16 µg/kg vs 10 µg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002; 29: 727–730.

    Article  PubMed  Google Scholar 

  10. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol 2002; 9 (3): 183–189.

    Article  PubMed  Google Scholar 

  11. Papayannopoulou T. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. Semin Hematol 2000; 37 (1, suppl 2): 11–18.

    Article  PubMed  CAS  Google Scholar 

  12. Levesque JP, Takamatsu Y, Nilsson SK, et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98 (5): 1289–1297.

    Article  PubMed  CAS  Google Scholar 

  13. Singhal S, Powles R, Kulkarni S, et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 501–505.

    Article  PubMed  CAS  Google Scholar 

  14. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18 (6): 1360–1377.

    PubMed  CAS  Google Scholar 

  15. Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88 (8): 3223–3229.

    PubMed  CAS  Google Scholar 

  16. Ilhan O, Arslan O, Arat M, et al. The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfusion Sci 1999; 20: 69–71.

    Article  CAS  Google Scholar 

  17. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98 (12): 3221–3227.

    Article  PubMed  CAS  Google Scholar 

  18. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99 (8): 2726–2733.

    Article  PubMed  CAS  Google Scholar 

  19. Miflin G, Russell NH, Hutchinson RM, et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Trans- plant 1997; 19: 9–13.

    CAS  Google Scholar 

  20. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.

    Article  PubMed  CAS  Google Scholar 

  21. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus Lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18 (3): 537–546.

    PubMed  CAS  Google Scholar 

  22. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs. filgrastimmobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995–1003.

    Article  PubMed  CAS  Google Scholar 

  23. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 335: 1231–1237.

    Article  Google Scholar 

  24. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95 (12): 3702–3709.

    PubMed  CAS  Google Scholar 

  25. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicentre comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood (first edition paper), www.hematologyjournal.org, accessed on June 20, 2002.

    Google Scholar 

  26. Anderlini P, Körbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90 (3): 903–908.

    PubMed  CAS  Google Scholar 

  27. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344 (3): 175–181.

    Article  PubMed  CAS  Google Scholar 

  28. Heldal D, Tjonnfjord G, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25 (11): 1129–1136.

    Article  PubMed  CAS  Google Scholar 

  29. Bennett CL, Waters TM, Stinson TJ, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 555–560.

    Article  PubMed  CAS  Google Scholar 

  30. Vigorito AC, Azevedo WM, Marques JFC, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145–1151.

    Article  PubMed  CAS  Google Scholar 

  31. Bacigalupo A, Zikos P, Van Lint M-T, et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exper Hematol 1998; 26: 409–414.

    CAS  Google Scholar 

  32. Russell JA, Larratt L, Brown C, et al. Allogeneic blood stem cells and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant 1999; 24: 1177–1183.

    Article  PubMed  CAS  Google Scholar 

  33. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90 (12): 4705–4709.

    PubMed  CAS  Google Scholar 

  34. Üstün C, Arslan O, Beksaç M, et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 1999; 5: 28–35.

    Article  PubMed  Google Scholar 

  35. Mahmoud H, Fahmy O, Kamel A, et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24 (4): 355–358.

    Article  PubMed  CAS  Google Scholar 

  36. Schmitz N, Beksaç M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLAidentical siblings with standard-risk leukemia. Blood 2002; 100: 761–767.

    Article  PubMed  CAS  Google Scholar 

  37. Vigorito AC, Marques Junior JF, et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Haematologica 2001; 86 (6): 665–666.

    PubMed  CAS  Google Scholar 

  38. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19 (16): 3685–3691.

    PubMed  CAS  Google Scholar 

  39. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98 (7): 2043–2051.

    Article  PubMed  CAS  Google Scholar 

  40. Schmitz N, Barrett J. Optimizing engraftment-Source and dose of stem cells. Semin Hematol 2002; 39 (1): 3–14.

    Article  PubMed  Google Scholar 

  41. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98 (6): 1695–1700.

    Article  PubMed  CAS  Google Scholar 

  42. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98 (6): 1739–1745.

    Article  PubMed  CAS  Google Scholar 

  43. Urbano-Ispizua A, Cameras E, Marin P, et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood fromhuman leukocyte antigen-identical siblings: detrimental effect of ahigh number of donor CD34(+) cells? Blood 2001; 98 (8): 2352–2357.

    Article  PubMed  CAS  Google Scholar 

  44. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94 (4): 1465–1470.

    PubMed  CAS  Google Scholar 

  45. Chen BJ, Cui X, Liu C, et al. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002; 99 (9): 3083–3088.

    Article  PubMed  CAS  Google Scholar 

  46. Uckun FM, Roers BA, Waurzyniak B, et al. Janus kinase 3 inhibitor WHI-Pi31/JANEX-1 prevents graftversus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002; 99: 4192–4199.

    Article  PubMed  CAS  Google Scholar 

  47. Baker J, Vemeris MR, Ito M, et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97 (10): 2923–2931.

    Article  PubMed  CAS  Google Scholar 

  48. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions afterbone marrow transplantation. Blood 1990; 75 (3): 555–562.

    PubMed  CAS  Google Scholar 

  49. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73 (6): 1720–1728.

    PubMed  CAS  Google Scholar 

  50. Le Blanc R, Montminy-Metivier S, Belanger R, et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001; 28 (9): 841–848.

    Article  PubMed  Google Scholar 

  51. Brunet S, Urbano-Ispizua A, Ojeda E, et al. Favourable effect of the combination of acute and chronic graftversus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114 (3): 544–550.

    Article  PubMed  CAS  Google Scholar 

  52. Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85 (6): 1659–1665.

    PubMed  Google Scholar 

  53. Elmaagacli A, Beelen DW, Opalka B, et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999; 94 (2): 384–389.

    PubMed  CAS  Google Scholar 

  54. Elmaagacli AH, Basoglu S, Peceny R, et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99 (4): 1130–1135.

    PubMed  CAS  Google Scholar 

  55. Conadini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17 (1): 208–215.

    Google Scholar 

  56. Powles R, Mehta J, Treleaven J, et al. Blood or BM for allogeneic transplantation from HLA-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM. Blood 2000; 96 (11): 196a [Abstract].

    Google Scholar 

  57. Hochberg EP, Chil1emi AC, Wu CJ, et al. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood 2001; 98 (4): 1116–1121.

    Article  PubMed  CAS  Google Scholar 

  58. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 2000; 95 (1): 352–359.

    PubMed  CAS  Google Scholar 

  59. Fujimaki K, MarutaA, YoshidaM, et al. Immune reconstitution assessed during five years afterallogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 27 (12): 1275–1281.

    Article  PubMed  CAS  Google Scholar 

  60. Shenoy S, Mohanakumar T, Todd G, et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant 1999; 23 (4): 335–346.

    Article  PubMed  CAS  Google Scholar 

  61. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001; 115 (3): 630–641.

    Article  PubMed  CAS  Google Scholar 

  62. Storek J, Gooley T, Witherspoon RP, et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997; 54 (2): 131–138.

    Article  PubMed  CAS  Google Scholar 

  63. Storek J, Espino G, Dawson MA, et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96 (9): 3290–3293.

    PubMed  CAS  Google Scholar 

  64. Tayebi H, Tiberghien P, Ferrand C, et al. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant 2001; 27 (2): 167–175.

    Article  PubMed  CAS  Google Scholar 

  65. S torek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97 (11): 3380–3389.

    Article  CAS  Google Scholar 

  66. S torek J, Witherspoon RP, Maloney DG, et al. Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. Blood 1997; 89 (10): 3891–3893.

    CAS  Google Scholar 

  67. Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88 (7): 2775–2779.

    PubMed  CAS  Google Scholar 

  68. Trenschel R, Bernier M, Delforge A, et al. Myeloid and lymphoid recovery following allogeneic bone marrow transplantation: a comparative study between related, unrelated bone marrow and allogeneic peripheral stem cell transplantation. Leuk Lymphoma 1998; 30 (3–4): 325–352.

    PubMed  CAS  Google Scholar 

  69. Zhang XF, Wang JF, Matczak E, et al. Janus kinase 2 is involved in stromal cell-derived factor-lalpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 2001; 97 (11): 3342–3348.

    Article  PubMed  CAS  Google Scholar 

  70. Link DC. Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization. Semin Hematol 2000; 37 (1, suppl 2): 25–32.

    Article  PubMed  CAS  Google Scholar 

  71. Steidl U, Kronenwett R, Rohr UP, et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34(+) hematopoietic stem cells. Blood 2002; 99 (6): 2037–2044.

    Article  PubMed  CAS  Google Scholar 

  72. Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant 2000; 26: 1–16.

    Article  PubMed  CAS  Google Scholar 

  73. Zeng D, Dejbakhash-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90 (1): 453–463.

    PubMed  CAS  Google Scholar 

  74. Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graftversus-host disease. Blood 1995; 86 (12): 4422–4429.

    PubMed  CAS  Google Scholar 

  75. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490.

    PubMed  CAS  Google Scholar 

  76. Reddy V, Hill GR, Pan L, et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graftversus-host disease through effects on the donor rather than the recipient. Transplantion 2000; 69 (4): 691–693.

    Article  CAS  Google Scholar 

  77. Zeng D, Hoffmann P, Lan F, et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood 2002; 99 (4): 1449–1457.

    Article  PubMed  CAS  Google Scholar 

  78. Atkinson K, Farrelly H, Cooley M, et al. Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow Transplant 1987; 2 (1): 51–57.

    PubMed  CAS  Google Scholar 

  79. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68 (3): 770–773.

    PubMed  CAS  Google Scholar 

  80. Anderlini P, Przepiorka D, Lauppe J, et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1997; 97 (2): 485–487.

    Article  PubMed  CAS  Google Scholar 

  81. Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3 (1): 45–49.

    PubMed  CAS  Google Scholar 

  82. de la Rubia J, Martinez C, Solano C, et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplant 1999; 24 (7): 723–728.

    Article  PubMed  CAS  Google Scholar 

  83. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.

    Article  PubMed  CAS  Google Scholar 

  84. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27 (7): 689–692.

    Article  PubMed  CAS  Google Scholar 

  85. Rowley SD, Donaldson G, Lilleby K, et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97 (9): 2541–2548.

    Article  PubMed  CAS  Google Scholar 

  86. Auquier P, Macquart-Moulin G, Moatti JP, et al. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplant 1995; 16: 541–547.

    PubMed  CAS  Google Scholar 

  87. Nishimori M, Yamada Y, Hoshi K, et al. Health-related quality of life of unrelated bone marrow donors in Japan. Blood 2002; 99 (6): 1995–2001.

    Article  PubMed  CAS  Google Scholar 

  88. Couban S, Messner HA, Andreou P, et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients. Biol Blood Marrow Transplant 2000; 6 (4A): 422–427.

    Article  PubMed  CAS  Google Scholar 

  89. Link H, Arseniev L, Bahre O, et al. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 1995; 86 (7): 2500–2508.

    PubMed  CAS  Google Scholar 

  90. Szer J, Curtis DJ, Bardy PG, et al. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial. Aust NZ J Med 1999; 29 (4): 487–493.

    Article  CAS  Google Scholar 

  91. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98 (12): 3186–3191.

    Article  PubMed  CAS  Google Scholar 

  92. Ji SQ, Chen HR, Xun CQ, et al. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation. Clin Transplant 2001; 15 (5): 317–323.

    Article  PubMed  CAS  Google Scholar 

  93. Isola L, Scigliano E, Fruchtman S. Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation. Biol Blood Marrow Transplant 2000; 6: 428–433.

    Article  PubMed  CAS  Google Scholar 

  94. Serody JS, Sparks SD, Lin Y, et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434–440.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Corey Cutler MD MPH FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph H. Antin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cutler, C., Antin, J.H. (2004). Stem Cell Sources. In: Soiffer, R.J. (eds) Stem Cell Transplantation for Hematologic Malignancies. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-733-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-733-8_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6588-5

  • Online ISBN: 978-1-59259-733-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation